Andrew Mark Brunner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Mark Brunner has a total of 473 co-authors. Here are the top co-authors by number of shared publications:
- Amir Tahmasb Fathi
Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, United States
38 shared publications - Philip C. Amrein
Massachusetts General Hospital, Boston, MA
32 shared publications - Areej El-Jawahri
Massachusetts General Hospital, Boston, MA
30 shared publications - Yi-Bin Chen
Massachusetts General Hospital
30 shared publications - Aj S. Bottoms
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
29 shared publications - Alice S. Mims
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
29 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6645-6660
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML
Pre-mRNA splicing gene mutations are common in MDS and CMML and induce R-loops which trigger ATR activation. We studied ceralasertib, an orally bioavailable ATR inhibitor, in adult patients with R/R MDS or CMML in a phase Ib/II study including a safety run-in and expansion of 160mg BID during a 28-day cycle on two schedules: days 1-14 (14on/14off) or days 1-7 and 15- 21 (7on/7off). Response rates and survival were estimated. Forty-four evaluable patients were treated. Grade 3 or higher all-cause adverse events in 10% or more patients included thrombocytopenia (n=13), anemia (n=12), neutropenia (n=9), febrile neutropenia (n=9), pneumonia (n=6), and hypoxia (n=5). Thrombocytopenia requiring a platelet transfusion during the first cycle was reduced to 1 of 10 patients on 7on/7off compared to 8 of 16 patients on 14on/14off among patients with a baseline platelet count >50k (p=0.087). ORR was 29.5% (13 of 44 patients) and included one CR, 5 marrow CR (2 with HI-N), and 7 with HI (HI-E=4, HI-N=2, HI-P=1). Median PFS was 4.8mo and OS was 12 months (95%CI 11, 24). ORR (p=0.72), PFS (p=0.9) and OS (p=0.65) did not differ between schedules. While splicing factor mutation VAFs were stable, RUNX1 mutation VAFs typically increased at progression. Serum inflammatory cytokine levels including TNFRSF8 (CD30) and other TNF family members decreased during ceralasertib exposure; this effect was blunted in RUNX1 mutant samples. In conclusion, ceralasertib 160mg BID d1-7 and 15-21 was established as monotherapy dosing with a response rate of 30% in patients with R/R MDS and CMML. NCT03770429
- 30 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6645-6660
Open AccessA Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML
Pre-mRNA splicing gene mutations are common in MDS and CMML and induce R-loops which trigger ATR activation. We studied ceralasertib, an orally bioavailable ATR inhibitor, in adult patients with R/R MDS or CMML in a phase Ib/II study including a safety run-in and expansion of 160mg BID during a 28-day cycle on two schedules: days 1-14 (14on/14off) or days 1-7 and 15- 21 (7on/7off). Response rates and survival were estimated. Forty-four evaluable patients were treated. Grade 3 or higher all-cause adverse events in 10% or more patients included thrombocytopenia (n=13), anemia (n=12), neutropenia (n=9), febrile neutropenia (n=9), pneumonia (n=6), and hypoxia (n=5). Thrombocytopenia requiring a platelet transfusion during the first cycle was reduced to 1 of 10 patients on 7on/7off compared to 8 of 16 patients on 14on/14off among patients with a baseline platelet count >50k (p=0.087). ORR was 29.5% (13 of 44 patients) and included one CR, 5 marrow CR (2 with HI-N), and 7 with HI (HI-E=4, HI-N=2, HI-P=1). Median PFS was 4.8mo and OS was 12 months (95%CI 11, 24). ORR (p=0.72), PFS (p=0.9) and OS (p=0.65) did not differ between schedules. While splicing factor mutation VAFs were stable, RUNX1 mutation VAFs typically increased at progression. Serum inflammatory cytokine levels including TNFRSF8 (CD30) and other TNF family members decreased during ceralasertib exposure; this effect was blunted in RUNX1 mutant samples. In conclusion, ceralasertib 160mg BID d1-7 and 15-21 was established as monotherapy dosing with a response rate of 30% in patients with R/R MDS and CMML. NCT03770429
- Open Access
- 4 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5320-5324
Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes
- 4 June 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5320-5324
Open AccessHematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes
- Top Cited Papers
- 9 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6794) , eady5196
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
Macrophages exert antitumorigenic activity through phagocytosis, but phagocytosis-enhancing therapeutics have not improved acute myeloid leukemia (AML) outcomes. To identify phagocytosis regulators, we performed CRISPR knockout screens in human AML cells cocultured with human macrophages. We found that the “don’t eat me” signal CD47 inhibited mouse but not human macrophage phagocytosis. However, O-linked glycosylation and sialylation were strong negative regulators of phagocytosis. In AML, the cell surface mucin-like glycoprotein CD43 was the major effector of these pathways. Inhibition of phagocytosis by CD43 was dependent on the length of its ectodomain and independent of the macrophage sialic acid receptors SIGLEC-1, SIGLEC-7, and SIGLEC-9. The inhibitory effects of CD43 extended beyond human macrophages to natural killer and T cells. Thus, CD43 forms a glyco-immune barrier that restrains both innate and adaptive antileukemic immunity.
- 9 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6794) , eady5196
Top Cited PapersSialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
Macrophages exert antitumorigenic activity through phagocytosis, but phagocytosis-enhancing therapeutics have not improved acute myeloid leukemia (AML) outcomes. To identify phagocytosis regulators, we performed CRISPR knockout screens in human AML cells cocultured with human macrophages. We found that the “don’t eat me” signal CD47 inhibited mouse but not human macrophage phagocytosis. However, O-linked glycosylation and sialylation were strong negative regulators of phagocytosis. In AML, the cell surface mucin-like glycoprotein CD43 was the major effector of these pathways. Inhibition of phagocytosis by CD43 was dependent on the length of its ectodomain and independent of the macrophage sialic acid receptors SIGLEC-1, SIGLEC-7, and SIGLEC-9. The inhibitory effects of CD43 extended beyond human macrophages to natural killer and T cells. Thus, CD43 forms a glyco-immune barrier that restrains both innate and adaptive antileukemic immunity.
- Open Access
Artificial intelligence-driven virtual tumor board enhances precision care in myelodysplastic syndromes
Background: Large language models (LLMs) perform well on standardized medical exam questions, but their reliability for complex hematology decision making is uncertain. We compared four general-purpose LLMs (GPT-4o, GPT-o3, Claude Sonnet 4, and DeepSeek-V3) with a Virtual MDS Panel (VMP), a coordinated multi-agent AI system in which domain-specialized, rule-bound software agents (WHO/ICC guidelines; IPSS-R/IPSS-M; NCCN) collaborate to generate tumor-board-level recommendations. Methods: Each model generated diagnostic, prognostic, and treatment recommendations for 30 myelodysplastic syndrome cases. Nine international MDS experts from five institutions, blinded to model identity, completed 3,000 structured ratings using 5-point Likert scales for diagnosis, prognosis, and therapy and classified errors by severity. Results: General-purpose LLMs achieved modest expert ratings (overall mean scores: 3.7 for GPT-o3, 3.2 for GPT-4o, 3.1 for DeepSeek, and 3.0 for Claude) and contained major factual errors in at least 24% of responses. The VMP increased the proportion of outputs rated 4 or higher to 87% (vs. 34-66% for general-purpose models), improved mean scores to 4.3 overall (4.3 for diagnosis, 4.4 for prognosis, and 4.1 for therapy), and reduced major errors to 8%. Conclusions: In this blinded evaluation of 30 complex MDS cases, general-purpose LLMs produced clinically important errors at rates that raise safety concerns for autonomous hematology decision making. The VMP, a rule-bound, multi-agent architecture, approached expert-level accuracy supporting its potential role as an effective decision-support tool for MDS in the future.
Open AccessArtificial intelligence-driven virtual tumor board enhances precision care in myelodysplastic syndromes
Background: Large language models (LLMs) perform well on standardized medical exam questions, but their reliability for complex hematology decision making is uncertain. We compared four general-purpose LLMs (GPT-4o, GPT-o3, Claude Sonnet 4, and DeepSeek-V3) with a Virtual MDS Panel (VMP), a coordinated multi-agent AI system in which domain-specialized, rule-bound software agents (WHO/ICC guidelines; IPSS-R/IPSS-M; NCCN) collaborate to generate tumor-board-level recommendations. Methods: Each model generated diagnostic, prognostic, and treatment recommendations for 30 myelodysplastic syndrome cases. Nine international MDS experts from five institutions, blinded to model identity, completed 3,000 structured ratings using 5-point Likert scales for diagnosis, prognosis, and therapy and classified errors by severity. Results: General-purpose LLMs achieved modest expert ratings (overall mean scores: 3.7 for GPT-o3, 3.2 for GPT-4o, 3.1 for DeepSeek, and 3.0 for Claude) and contained major factual errors in at least 24% of responses. The VMP increased the proportion of outputs rated 4 or higher to 87% (vs. 34-66% for general-purpose models), improved mean scores to 4.3 overall (4.3 for diagnosis, 4.4 for prognosis, and 4.1 for therapy), and reduced major errors to 8%. Conclusions: In this blinded evaluation of 30 complex MDS cases, general-purpose LLMs produced clinically important errors at rates that raise safety concerns for autonomous hematology decision making. The VMP, a rule-bound, multi-agent architecture, approached expert-level accuracy supporting its potential role as an effective decision-support tool for MDS in the future.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Marrow IDH1 VAF prior to Transplant and Maintenance
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia
Representativeness of Study Participants
- 9 June 2025
- Published by Elsevier in Leukemia Research
- Vol. 156, 107735
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome
- 9 June 2025
- Published by Elsevier in Leukemia Research
- Vol. 156, 107735
Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome